Recombinant immunoreceptors are modularily composed of extracellular antigen binding and intracellular signalling domains that are preferentially derived from CD3z or FceRIg. The impact of the signalling domain on the stability of immuoreceptor expression and function is not completely understood. To address this issue, we generated and expressed a panel of recombinant z-and g-chain immunoreceptors, respectively, in human peripheral blood T cells. The expression level of z-chain immunoreceptors in human T cells is significantly lower than those of the homologous gchain receptors. Low z-chain receptor expression in peripheral T cells is because of the intracellular signalling domain and independent of the FceRIg or CD3z transmembrane region. Expression of both receptors decreases upon prolonged cultivation. Shortly after receptor engraftment, target cell lysis and induction of IFN-g secretion are mediated with similar efficiency by z-and g-chain immunoreceptors. Upon prolonged propagation, however, T-cell activation mediated by z-chain immunoreceptors is more efficient than by g-chain receptors, indicating that the initial high expression level of g-chain immunoreceptors compensates its lower activation capacity. Consequently, g-chain immunoreceptors exhibit a higher threshold value for specific activation and are more pronouncedly inhibited by soluble ligand antigen compared to the homologous z-chain receptor. These findings have substantial consequences for the design of recombinant immunoreceptors for use in adoptive immunotherapy.
Introduction
Upon specific binding to antigen, recombinant immunoreceptors with antibody-like specificity direct both CD4 + and CD8 + T cells to highly efficient, MHCindependent cellular activation against antigen-expressing target cells. [1] [2] [3] The antigen-binding domain of these receptors consists of an antibody-derived single-chain fragment (scFv). The scFv domain is linked either directly or via an extracellular spacer to a transmembrane and intracellular signalling moiety that is derived either from the CD3 z-chain or from the highly homologous FceRIg-chain. 4, 5 CD3z and FceRIg are part of the CD3/TCR complex and of several Fc receptors, respectively, [6] [7] [8] and can partially substitute each other in several model systems. 8, 9 For instance, T-cell receptor complexes that have a deleted CD3 z-chain are complemented by the FceRIg chain to functional activity. However, they are expressed at substantially lower densities on the cell surface than the physiological CD3z/TCR complex, 9 implying that the g-chain only insufficiently substitutes CD3 z-chain functions. The molecular basis of this inter-receptor complementation, however, is yet not fully understood.
We and others recently demonstrated that an extracellular domain inserted between the antigen-binding site and the signalling domain of the immunoreceptor has significant impact on the stability of receptor expression and on effector cell activation upon receptor crosslinking by antigen. [10] [11] [12] Recombinant z-chain receptors, in contrast to g-chain receptors, require an extracellular spacer domain for functional expression in T cells. 12 Although the requirements for functional expression of recombinant g-and z-chain receptors are obviously different, it remains unresolved how the transmembrane and/or intracellular signalling domain affects the stability of recombinant receptor expression on the cell surface and receptor-mediated cellular activation of grafted T cells. To address this issue, we generated a panel of recombinant immunoreceptors that consist extracellularily of the same antigen binding and spacer domain, whereas the transmembrane region and/ or intracellular domain is derived from CD3z or, alternatively, FceRIg. After expression of the g-and zchain immunoreceptors, we recorded (i) the stability of recombinant receptor expression in peripheral blood T cells, (ii) the receptor-mediated cellular activation at different time points after receptor engraftment, and (iii) the receptor-mediated cellular activation by g-and z-chain receptors against tumor cells in the presence of soluble ligand antigen.
Results
Recombinant g-and z-chain immunoreceptors are expressed in a different fashion in human peripheral blood T cells
To analyze the impact of the signalling domain on the expression of recombinant immunoreceptors in human peripheral blood T cells and to dissect the role of the FceRIg versus CD3z-derived transmembrane domain, we generated expression cassettes for a panel of recombinant receptors that were inserted into the retroviral vector pBullet 13, 14 for expression in human peripheral blood T cells. These receptors harbor the same extracellular antigen binding and spacer domains with specifcity for the tumor antigens CA72-4, CA19-9, and CEA, respectively ( Figure 1 ; Table 1 Figure 2 and Figure 1 Expression cassettes for the recombinant immunoreceptors used in this study. The numbers indicate the aminoacids of the FceRIg-, CD3z-and CD28-chain constituting the transmembrane (TM) and intracellular (IC) signalling domains of the immunoreceptor.
Impact of signalling domains on chimeric receptor expression C Heuser et al Figure 2 Expression of recombinant receptors in peripheral blood T cells. Peripheral blood T cells were retrovirally grafted with different scFv-Fc-g/g or scFv-Fc-z/z receptors (a-f), scFv-Fc-z/g (h) or scFv-Fc-g/z (k) receptors and scFv-Fc-CD28/CD28 (g) or scFv-Fc-CD28/CD28-z (j) immunoreceptors, and stained simultanously with PE-conjugated anti-CD3 and FITC-conjugated anti-human IgG Fc antibodies. For control, non-transduced (i) or T cells that were transduced with an empty expression vector (l) were also stained with anti-CD3 and anti-human IgG antibodies. The cells were analyzed by flow cytometry and the data presented as dot plots.
Impact of signalling domains on chimeric receptor expression C Heuser et al summarized in Figure 3 and Table 1 , retroviral transduction of peripheral blood lymphocytes resulted in highly efficient expression of all tested immunoreceptors. Noteworthy, the recombinant scFv-Fc-g/g receptors appear to be consistently expressed in higher densities on the cell surface of peripheral blood T cells than the homologous scFv-Fc-z/z chain receptors (Figures 2 and  3) . In contrast, all receptors were expressed in similar densities on the surface of TCR À human 293T cells (data not shown). Impact of signalling domains on chimeric receptor expression C Heuser et al
We asked whether the observed differences in expression are because of the intracellular CD3z and FceRIg signalling domains, respectively, or their transmembrane regions that are highly homologous. 15 As demonstrated in Figures 2 and 3 , the recombinant scFv-Fc-g/z receptor is expressed in a lower density on the cell surface of grafted T cells than the corresponding scFv-Fc-z/g receptor indicating that the different expression patterns result rather from the intracellular signalling moiety than the transmembrane domain. This is further substantiated by the observation that engraftment of an intracellular CD3z signalling domain to a recombinant immunoreceptor that harbors a CD28-derived transmembrane and intracellular signalling domain 16 also substantially impairs the level of receptor expression on the cell surface (Figures 2 and 3) .
Comparison of recombinant scFv-Fc-g/g and scFv-Fcz/z receptor expression with receptor-mediated T-cell activation
We analyzed how the intracellular CD3z-or FceRIg-chain of the recombinant immunoreceptor affects its expression and receptor-mediated cellular activation of grafted T cells early after retroviral engraftment and upon prolonged cell culture, respectively. T cells from the peripheral blood of two different donors (donors A, H) were grafted with two different sets of homologous scFvFc-g/g and scFv-Fc-z/z receptors, respectively, and the number of CD3 + T cells with recombinant receptor expression was continuously monitored by flow cytometry over 37 days. We monitored recombinant receptor expression utilizing a PE-conjugated anti-human IgG Impact of signalling domains on chimeric receptor expression C Heuser et al antibody that is much more, sensitive for detection than the corresponding FITC-conjugated antibody (data not shown). T cells were regarded positive for recombinant receptor expression at a cutoff value defined by 499% nontransduced T cells beyond this value. Herewith, we obtained nearly homogeneous T-cell populations with initial expression rates of recombinant g-and z-chain receptors in 60-80% of the total cell population. We recorded the number of T cells with receptor expression and, the red mean fluorescence of the whole-cell population and of those cells above the cutoff value as an indicator for the density of recombinant receptor expression on the cell surface. As summarized in Figure 4 , the number of T cells with detectable amounts of recombinant g-or z-chain immunoreceptors decreased within 5-10 days from initially similar numbers and remained nearly constant thereafter (Figure 4a -c). Compared to scFv-Fc-g/g receptor grafted T cells, however, the number of T cells with detectable amounts of scFv-Fcz/z receptors decreased to substantially lower numbers. Concomitantly, the density of expression of both recombinant g-and z-chain immunoreceptors on the cell surface also decreased over the first 5-10 days of cultivation as well, the expression of the z-chain receptor, however, being constant at a lower level than those of the homologous g-chain receptor (Figure 4d -f). This phenomenon is unlikely to be because of different growth kinetics of transduced and nontransduced T cells because the density of the recombinant receptor on the cell surface of those T cells that were gated for detectable receptor expression decreased in a similar fashion (Figure 4g -i).
We compared the efficiency of cellular activation mediated by g-and z-chain receptors early after retroviral engraftment compared to day 37 of continuous cell culture in the presence of IL-2. Thus, we recorded IFN-g secretion and specific target cell lysis by anti-CEA receptor grafted T cells from donors A and H (cf. Figure  4b ,c,e,f,h,i) against LS174T and LS-C tumor cells that express similar amounts of the CEA target antigen. Initially, recombinant g-(BW431/26-scFv-Fc-g/g) and zchain (BW431/26-scFv-Fc-z/z) receptor grafted T cells lysed CEA + tumor cells with similar efficiency. Upon prolonged cultivation, however, target cell lysis by T cells grafted with the g-chain receptor was substantially reduced, whereas lysis by z-chain receptor grafted T cells was not altered ( Figure 5 ). Accordingly, both g-and z-chain receptor grafted T cells secreted initially similar high amounts of IFN-g upon cocultivation with CEA + tumor cells. After propagation for 37 days, however, zchain receptor grafted T cells secreted IFN-g with higher efficiency upon cocultivation with CEA + tumor cells than g-chain receptor grafted T cells, although at much lower levels than on day 1 ( Figure 5 ). These findings are noteworthy taking into account that initially the number of T cells that express the recombinant z-chain receptor was only slightly lower for both donors than the number of T cells with g-chain receptor expression (about 60 versus 70%). Upon prolonged cultivation, however, the number of T cells with detectable amounts of the z-chain receptor decreased to about 20%, whereas the number of T cells equipped with the g-chain receptor was still about 40% (cf. Figure 4b ,c). Antigen-negative target cells did not activate receptor grafted T cells, neither shortly after receptor graftment nor upon prolonged cultivation (not shown). In summary, recombinant g-chain-receptor mediated T-cell activation against antigen-positive target cells is initially similarily efficient than that mediated by the z-chain immunoreceptor, but becomes much less effective upon prolonged cultivation of receptor grafted T cells, although the g-chain receptor is more stably expressed than the z-chain receptor.
Recombinant g-and z-chain receptors activate grafted T cells at different thresholds A high expression level of recombinant g-chain receptors on the cell surface of grafted T cells may initially Impact of signalling domains on chimeric receptor expression C Heuser et al compensate a low cell activation capacity compared to the homologous z-chain receptor. We therefore asked whether these properties reflect different activation thresholds of g-and z-chain receptors. Peripheral blood T cells were grafted with recombinant anti-CEA-g/g orz/z receptors and anti-CA72-4-g/g, -g/z, -z/g or -z/z receptors, respectively, that harbor intracellularily CD3z or FceRIg-derived signalling domains joined either to a gor z-chain-derived transmembrane domain (cf. Table 1) . Grafted T cells were stimulated with increasing amounts of plastic immobilized mucin-antigen bovine submaxillary mucin (BSM) or anti-idiotypic mAbs (BW2064/36, BW2064/399) with different binding affinities for the recombinant anti-CEA receptors. As demonstrated in Figure 6a and b, stimulation of anti-CEA-receptor grafted T cells by anti-idiotypic antibodies resulted in a dosedependent cellular activation of grafted T cells indicated by IFN-g secretion with a plateau at 40.1 and 41 mg/ml, respectively, of the stimulating antibody. Remarkably, the threshold of receptor-mediated cellular activation was dependent on both the binding affinity of the stimulating antibody and the intracellular signalling domain of the receptor with a higher threshold for the g-compared to the z-chain receptor. Accordingly, the activation threshold of the anti-CA72-4 receptor depends also on the intracellular signalling domain with a lower threshold for z-than g-chain receptors independent of whether the receptor's transmembrane domain is derived from CD3z or FceRIg (Figure 6c ). These data demonstrate that the recombinant g-chain receptor activates grafted T cells with lower sensitivity for antigen than the homologous z-chain receptor and consequently requires higher amounts of immobilized antigen for maximum activation.
Recombinant Figure 7 , recombinant anti-CA19-9-Fc-z and -g receptors activate grafted T cells with similar efficiency against CA19-9 + LS-C tumor cells resulting in highly efficient target cell lysis and IFN-g secretion. Antigen-negative A375 cells did not activate anti-CA19-9 receptor grafted T cells (not shown). We cocultivated T cells equipped with recombinant anti-CA19-9-g and -z receptors, respectively, with CA19-9 + LS-C tumor cells that do not secrete the CA19-9 antigen in substantial amounts in the presence of serial dilutions of cell culture supernatants derived from H498 tumor cells that secrete high amounts of CA19-9. The CA19-9 concentration of the H498 supernatant was about 20 000 U/ml as determined by ELISA. As summarized in Figure 8 , both anti-CA19-9-scFv-Fc-g and -z receptors activate grafted T cells with similar efficiency against LS-C cells in the presence of the CA19-9
À cell culture supernatant derived from CA19-9-negative H716 tumor cells. In the presence of CA19-9 + H498 cell culture supernatant, NS19-9-scFv-Fc-g/g receptor mediated lysis of CA19-9 + LS-C cells was substantially inhibited, whereas cytolysis by NS19-9-scFv-Fc-z/z grafted effector cells was not significantly affected (Figure 8a,b) . IFN-g secretion by NS19-9-scFv-Fc-z/z receptor grafted T cells is inhibited by 30-fold higher concentrations of ligand antigen compared to INF-g secretion by NS19-9-scFvFc-g/g receptor grafted cells. Remarkably, we did not 
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C Heuser et al observe any effect on NS19-9scFv-Fc-z/z receptormediated target cell lysis, whereas soluble antigen partially blocked NS19-9scFv-Fc-z/z receptor-mediated IFN-g secretion implying that the effector functions mediated by the recombinant immunoreceptor are executed with different signalling thresholds.
Discussion
We compared a panel of recombinant immunoreceptors with respect to their impact on stability of expression on the cell surface and to their capability to mediate cellular activation. The immunoreceptors used in this study harbor identical extracellular antigen binding and spacer domains but different transmembrane and intracellular signalling moities that are derived from the g-chain of the FceRI receptor, the z-chain of the CD3/TCR complex, and the CD28 costimulatory molecule, respectively. The following findings imply that the intracellular signalling domain affects substantially the stability and function of receptor expression and the efficiency of receptormediated cellular activation: (i) Recombinant g-chain 18 moreover demonstrating that a chimeric CD4-z chain receptor compared to the homologous gchain receptor induces a substantially higher cellular Impact of signalling domains on chimeric receptor expression C Heuser et al activation when expressed in FcR + effector cells. In contrast to the situation in Fc receptor positive non-T cells, the efficiency of T-cell activation by recombinant gor z-chain receptors and the stability of receptor expression in T cells is less obvious. We found that in TCR + peripheral blood T cells recombinant z-chain receptors are expressed with lower stability than their g-chain counterparts. This is mainly because of the intracellular signalling part of the receptor molecule because reciprocal exchange of the highly homologous FceRIg and CD3z transmembrane domains did not substantially affect recombinant receptor expression. Moreover, engraftment of a recombinant CD28-based immunoreceptor with the intracellular CD3z-signalling domain also impairs its expression on the cell surface of T-cell substantially. Differential expression of CD3 z-and FceRI g-chain-based immunoreceptors on the cell surface of T cells may explain some apparent contradictional observations. Ren-Heidenreich et al 19 reported that recombinant g-and z-chain immunoreceptors activate grafted peripheral blood T cells with similar efficiency whereas Haynes et al 20 reported a superior in vivo efficiency of z-chain receptor grafted T cells. We here found that, initially, g-chain receptor grafted T cells induce an antitumor response with similar efficiency than T cells equipped with the z-chain receptor (cf. Figure  5 ). This implies that in T cells the high cell surface expression of g-chain receptors compensates, at least partially, the more potent cell activation properties of the homologous z-chain receptors. This conclusion is in accordance with recent findings that demonstrate a direct correlation between the amount of recombinant receptor molecules on the surface of effector cells and the antigen density on the target cell, respectively, and the efficiency of receptor-mediated target cell lysis.
14 Upon prolonged cultivation of receptor grafted cells, however, the expression level of both recombinant g-and z-chain receptors and as a result the number of T cells with detectable amounts of g-or z-chain immunoreceptors on the cell surface decreases. Concomitantly, we found that the efficiency of g-chain receptor-mediated activation of effector cells decreases much faster than those mediated by the z-chain receptor (cf. Figure 5 ). This may explain the more efficient in vivo antitumor capacity of z-chain receptor grafted T cells compared to T cells expressing the homologous g-chain receptor 20 because the in vivo efficacy depends basically on a more sustained antitumor reactivity of receptor grafted T cells. Accordingly, although initially similarly efficient, z-chain receptor grafted T cells are expected to be superior to g-chain receptors with respect to achieve a long-lasting antitumor response in vivo. These findings are also in accordance with a higher activation threshold for g-chain receptor grafted T cells compared to T cells grafted with the homologous z-chain receptor. High levels of g-chain receptor expression on the cell surface compensate initially for a higher activation threshold, but decrease of receptor expression will affect T-cell activation more substantially. Moreover, cellular activation of g-chain receptor grafted T cells is much more affected by soluble tumor antigen, that is frequently present in high concentrations in the tissues of tumor patients, than T cells grafted with the homologous z-chain receptor. Accordingly, the therapeutic in vivo efficacy of g-chain receptor grafted T cells will be limited despite a higher expression level on the surface of grafted T cells. On the other hand, recombinant g-chain immunoreceptors may limit an anti-tumor response much earlier preventing autoaggression of receptor grafted T cells. Under this point of view, the intracellular signalling domain can be utilized to fine-tune a recombinant receptor-mediated immune response and to limit a cellular immune response to those targets with high expression of the target antigen.
14 The higher intrinsic signalling capacity of z-chain immunoreceptors may be because of differences in structure of the z-and g-subunit, respectively, that differ in two ways: (i) z-and g-chains contain different numbers of ITAMs, that is, three versus one ITAM motifs and (ii) the spacing and flanking amino acids differ between z-and g-chains. Although there is obviously a direct quantitative relation between the number of z-chain ITAMs and the efficiency of cytokine release and thymocyte selection, 21, 22 different flanking regions of the conserved ITAM motifs, however, may also influence signalling and effector functions. On the other hand, impaired cell surface expression of z-chain immunoreceptors can be functionally compensated by the combination of different signalling domains like CD28 and CD3z. We and others have recently demonstrated that in peripheral blood T cells, combined chimeric T-cell receptor signalling via CD28 and CD3z resulted in qualitatively and quantitatively improved cytokine secretion and enhanced proliferation of receptor grafted T cells. [23] [24] [25] In summary, our data demonstrate that the intracellular signalling domain of recombinant immunoreceptors substantially affects receptor expression and function in grafted T cells. Previous studies indicate that dependent on the intracellular signalling domain and the type of grafted effector cell, the recombinant receptor may require an additional extracellular spacer domain for stable expression 11, 12 that in turn also impacts its cell activation properties. 10, 11 A rational design for the generation of highly efficient recombinant T-cell immunoreceptors must address both the receptor's cell surface expression and its cell activation properties that in turn modulate effector cell activation during prolonged propagation of receptor grafted T cells and the functional discrimination of membrane bound versus soluble target antigen required for efficient target cell elimination. On the other hand, our growing knowledge about the function of modularily composed immunoreceptors facilitates also the generation of receptors that exhibit restricted cellular activation properties thereby limiting the cellular response upon repeated restimulation.
Materials and methods

Cell lines and antibodies
293T cells are human embryonal kidney cells that express the SV40 large T antigen.
26 LS174T (ATCC CCL 188) is a CEA-expressing colon carcinoma cell line, A375 (ATCC CRL 1619) is a melanoma cell line, H498 (ATCC CCL 254) is a colon carcinoma cell line that secretes high amounts of CA19-9, H716 (ATCC CCL251) is a CA19-9 À colon carcinoma cell line, OKT3 (ATCC CRL 8001) and NS19-9 (ATCC HB 8059) are hybridoma cell lines that produce the anti-CD3 mAb OKT3 and anti-CA19-9 mAb NS19-9, respectively (all obtained from ATCC, Rockville, MD, Impact of signalling domains on chimeric receptor expression C Heuser et al USA). LS-C cells are derived from LS174T cells and express similar amounts of CEA but substantially higher levels of the CA19-9 tumor antigen. 27 293T cells were cultured in DME medium supplemented with 10% (v/v) FCS, all other cell lines were cultured in RPMI 1640 medium, 10% (v/v) FCS (all Life Technologies, Paisly, UK). For prolonged cultivation, receptor grafted peripheral T cells were incubated in the presence of 400 U/ml IL-2 in standard culture medium. The culture medium was weekly changed twice. OKT3 and NS19-9 mAbs were affinity purified from hybridoma supernatants utilizing goat anti-mouse IgG2a or anti-mouse IgG1 antibodies (Southern Biotechnology, Birmingham, AL, USA) that were immobilized on N-hydroxy-succinimideester-(NHS)-activated sepharose as recommended by the manufacturer (Amersham Biosciences, Freiburg, Germany). MAb NS19-9 was biotinylated utilizing NHSactivated biotin (Amersham Biosciences) as recommended by the manufacturer. The phycoerythrin-(PE)-conjugated anti-CD3 mAb UCHT1 was purchased from Dako, Hamburg, Germany. The goat anti-human IgG antibody and its FITC-and PE-conjugated F(ab ) 2 derivative were purchased from Southern Biotechnology, Birmingham, AL, USA. The anti-human IFN-g mAb NIB42, the anti-mouse IL-2 mAb JES6-1A12, the biotinylated anti-human IFN-g, and anti-mouse IL-2 mAbs 4S.B3 and JES6-5H4, respectively, were purchased from BD Pharmingen, San Diego, CA, USA.
Generation of CA19-9 containing cell culture supernatant H498 (CA19-9 + ) and H716 (CA19-9 À ) tumor cells were cultivated in RPMI 1640+10% FCS. The supernatant was collected and dialyzed against fresh RPMI 1640 + 10% FCS, prior to use. The content of CA19-9 was determined by ELISA utilizing the anti-CA19-9 mAb NS19-9 (1mg/ ml) for capture and biotinylated NS19-9 mAb (0.5 mg/ml) for detection. The reaction product was visualized by a peroxidase-streptavidin-conjugate (1:10 000) and ABTS s (both purchased from Roche Diagnostics, Mannheim, Germany). The CA19-9 content was quantified utilizing purified CA19-9 antigen (Calbiochem-Novabichem, San Diego, CA, USA) as a standard. Figure 1 and Table 1 summarize the recombinant immunoreceptors that were used for this study. The generation and expression of the CEA-specific BW431/ 26-scFv-Fc-g/g, BW431/26-scFv-Fc-z/z, BW431/26-scFvFc-CD28/CD28, and BW431/26-scFv-Fc-CD28/CD28-z receptors and of the CA72-4-specific CC49-scFv-Fc-g/g and CC49-scFv-Fc-z/z receptors were recently described in detail. 3, 16, 23, 28, 29 The anti-CA19-9-scFv was isolated from NS19-9 hybridoma cells by means of the recombinant phage antibody system (Amersham Biosciences). The resulting scFv-antibody retained specific antigen binding compared to the parental mAb NS19-9 mAb (unpublished data). To generate the retroviral expression cassettes for CA19-9-specific recombinant immunoreceptors, the NS19-scFv DNA was amplified by PCR and herewith flanked by NcoI (5 0 ) and BglII (3 0 ) restriction sites, respectively, utilizing the following set of oligonucleotide primers: 5 0 -CTA CGT ACC ATG GAT TTT CAG GTG CAG ATT TTC-3 0 (sense) and 5 0 -GGT TCC AGC AGA TCT GGA TAC GGC-3 0 (antisense, restriction sites are underlined). The anti-CEA receptor DNA in pBullet 14, 16 was cleaved by NcoI and BamHI and the BW431/ 26-scFv DNA was replaced by the digested NS19-9-scFv PCR product. The expression cassettes of the variant CC49-scFv-Fc-g/z and CC49-scFv-Fc-z/g immunoreceptors harboring either a g-chain-derived transmembrane region that was fused to the intracellular signalling domain of CD3z or vice versa a CD3z-derived transmembrane domain fused to the intracellular signalling domain of the FceRIg chain were generated as follows: the cDNA coding for the intracellular signalling domain of CD3z and FceRIg, respectively, was PCR-amplified utilizing the following oligonucleotids comprising sequences for the transmembrane regions of CD3z and FceRIg and for BamHI and XhoI restriction sites, respectively:
Generation of recombinant immunoreceptors
0 (z/g-sense), 5 0 -CTGC TACTCGAGGACTAAAGCTACTGTGGTGGTTTCTC ATG-3 (z/g-antisense; restriction sites are underlined). Herewith, the sequences coding for the transmembrane regions of CD3z and FceRIg, respectively, were substituted with each other. The CC49-scFv-Fc-g/g receptor DNA in pBullet was cleaved by BamHI and XhoI, respectively, and the g/g sequences were replaced by the digested g/z and z/g PCR product.
Expression of recombinant immunoreceptors
To express recombinant receptors in T cells from the peripheral blood, the expression cassettes were inserted into the retroviral vector pBullet 13, 14 as recently described. 23 Retroviral transduction of peripheral T cells with recombinant receptors was described in detail elsewhere 13, 14, 16, 26, 28 and receptor expression was monitored by flow cytometric analysis. Recombinant receptors were also expressed in 293T cells after transfection of the retroviral expression vector by calcium phosphate coprecipitation (20 mg DNA/2 Â 10 6 cells). Cells were harvested after 48 h and subjected to analysis.
Immunofluorescence analysis
Recombinant immunoreceptors on 293T cells were detected by an FITC-conjugated F(ab 0 ) 2 anti-human IgG1 antibody (1 mg/ml). Recombinant receptor grafted T cells were identified by two-color immunofluorescence utilizing a PE-or FITC-conjugated F(ab 0 ) 2 anti-human IgG1 antibody (1 mg/ml) and a FITC-or PE-conjugated anti-CD3 mAb (UCHT-1, 1:20). Immunofluorescence was analyzed using a FACScant cytofluorometer equipped with the CellQuest research software (Becton Dickinson, Mountain View, CA, USA). To identify T cells with recombinant receptor expression, we set markers with 99% of nontransduced T cells beyond. The mean fluorescene intensity of the resulting CD3/recombinant receptor double-positive T-cell population was determined. The results from several independent experiments utilizing T cells from different healthy blood donors for each experiment were summarized and differences of receptor densities on the cell surface of Impact of signalling domains on chimeric receptor expression C Heuser et al grafted T cells were analyzed by Student's t-test for independent samples utilizing the SPSS analysis software 11.0.1 (SPSS Inc., Chicago, IL, USA).
Receptor-mediated activation of grafted T cells from peripheral blood T cells (1 Â 10 5 /well), grafted with recombinant scFv-Fcg/g, scFv-Fc-z/g, scFvFc-g/z, and scFv-Fc-z/z receptors, respectively, were cultivated in microtiterplates that were coated with different amounts of anti-CEA-receptor specific anti-idiotypic mAbs (BW2064/36, BW2064/399; 0.01-10 mg/ml) or BSM-surrogate antigen (0.5-50 mg/ml) (Sigma, Deisenhofen, Germany) carrying the epitope of the recombinant anti-TAG72 receptor. 29, 30 After 48 h, supernatants were removed and analyzed by ELISA for IFN-g secretion as described below. In a second set of experiments T cells grafted with anti-CEA-or anti-CA19-9-scFv-Fc-g/g and -z/z receptors, respectively, were cocultivated (1.25 Â Briefly, IFN-g in the supernatant was bound to the solidphase anti-human IFN-g mAb NIB42 (1 mg/ml) and detected by the biotinylated anti-human IFN-g mAb 4S.B3 (0.5 mg/ml). The reaction product was visualized by a peroxidase-streptavidin-conjugate (1:10 000) and ABTS 
